Septic thrombophlebitis with persistent methicillin-resistant Staphylococcus aureus bacteremia and de novo resistance to vancomycin and daptomycin

Yael Koton,1,2 Zafrir Or,3 Naiel Bisharat1,2
1Department of Medicine D, Emek Medical Center, Afula; 2Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa; 3Department of Cardiology, Emek Medical Center, Afula, Israel

Abstract
Persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with significant risk of mortality, especially when it occurs on appropriate antimicrobial therapy. We herein describe an unusual case of a patient with prosthetic aortic tissue valve, who suffered from central venous catheter related MRSA bacteremia with septice thrombus formation in the superior vena cava. MRSA bacteremia persisted despite removal of the catheter and appropriate antimicrobial therapy including vancomycin, rifampin, and daptomycin. Subsequently, the MRSA strain exhibited de novo resistance to vancomycin, rifampin and daptomycin. Eventually, salvage combination therapy with high dose daptomycin and trimethoprim-sulfamethoxazole was successful and achieved clearance of MRSA bacteremia. The case illustrates the growing complexity of treating MRSA infections.

Introduction
Persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is a challenging clinical problem that carries a significant risk for mortality and raises concerns because it develops despite the administration of appropriate antimicrobial therapy.1 Previous studies have identified several risk factors that are associated with the development of persistent MRSA bacteremia such as endocarditis, retained central venous catheters, metastatic infection, and congestive heart failure.1,2 We describe a patient who suffered from persistent MRSA bacteremia secondary to septic thrombus formation in the superior vena cava (SVC) with emergence of resistance to vancomycin and daptomycin while on therapy.

Case Report
A 50-year-old man was admitted to the emergency department due to high spiking fever and disorientation. His past medical history was remarkable for antiphospholipid syndrome with previous episodes of deep vein thrombosis and ischemic stroke, for which he was treated with warfarin. In addition, he underwent prosthetic tissue aortic valve replacement due to aortic stenosis. Three months prior to present admission he was admitted to another hospital due to brainstem hemorrhage that was complicated with nosocomial pneumonia and severe renal failure for which he received hemodialysis via permacath. Anticoagulant therapy was switched from warfarin to subcutaneous enoxaparin upon partial recovery of his kidney function. The permacath was retained until achievement of full recovery of kidney function. The patient did not attend a scheduled appointment for permacath removal. Vital signs upon admission showed a temperature of 39°C, blood pressure of 80/50 mmHg, pulse of 128 beats per minute, 36 breaths per minute, and oxygen saturation of 88% on room air. His physical examination was remarkable for disorientation without any obvious foci of infection, including entry site of the permacath. Blood tests showed leukocytosis of 20,000 per cubic millimeter, hemoglobin concentration of 12 g/dL, platelets count of 550,000 per cubic millimeter, blood urea nitrogen and creatinine levels were slightly elevated. His chest x-ray was normal, urine analysis showed microscopic hematuria, blood and urine were drawn for culture. The permacath was extracted and the patient was treated with vancomycin, piperacillin-tazobactam, amikacin, vasopressors and admitted to intensive care unit (ICU). His blood cultures grew MRSA susceptible to vancomycin, rifampin, and daptomycin (MIC=1.5 μg/mL) but without success. Transesophageal echocardiogram (TEE) showed a thrombus measuring 8 mm (width) by 8 mm (length) in the SVC, approximately 2.2 cm before entry into the right atrium (Figure 1). A whole body computed tomography scan failed to show any other foci of infection. The antimicrobial therapy was switched to daptomycin (10 mg/kg) plus oxacillin, but the patient was still bacteremic with MRSA. However, the strain became non-susceptible to daptomycin (MIC=1.5 μg/mL) and resistant to oxacillin, but the patient was still bacteremic with MRSA. However, the strain became non-susceptible to daptomycin (MIC=1.5 μg/mL) and resistant to vancomycin (MIC=2 μg/mL). At this stage, daptomycin dose was increased to maximum (12 mg/kg) and intravenous TMP/SMX was added to daptomycin (Table 2), this combination treatment eventually yielded a satisfactory response with clearance of MRSA bacteremia within 5 days. The patient continued treatment with enoxaparin and maintained therapeutic anti Xa levels, his condition stabilized and serial blood cultures were sterile. Unfortunately, one day prior to a scheduled TEE study the patient suffered a cardiac arrest with an ini-
tial cardiac rhythm of asystole and eventually died. Molecular characterization (multilocus sequence typing and spa typing), carried out as previously described, showed that all MRSA strains obtained throughout the patient’s hospitalization belonged to the same genotype (sequence type 5, spa type t002).

Discussion

Septic thrombus formation is a condition characterized by venous thrombosis, inflammation, and bacteremia. Septic thrombophlebitis can affect peripheral, central, portal, pelvic, or intracranial venous sinuses. Septic thrombophlebitis of the SVC is mainly associated with central venous catheter placement, other causes include burns, hyper-coagulable conditions, and administration of total parenteral nutrition. Successful treatment includes removal of any indwelling catheters combined with appropriate antimicrobial therapy. The patient described above suffered from MRSA bacteremia that persisted despite removal of central venous catheter and appropriate antimicrobial therapy.

Most cases of SVC thrombosis are related to the presence of indwelling intravascular devices, malignancy, and hypercoagulable conditions, two of which existed in the current case. The preferred management of asymptomatic and hemodynamically stable patients is anticoagulation, while thrombectomy and thrombolysis are indicated in massive thrombosis with hemodynamic instability, and pulmonary embolism. Balloon angioplasty and stent insertion is usually indicated in patients with chronic obstructions and SVC syndrome. Treatment of persistent MRSA bacteremia is a challenging clinical problem especially with emergence of resistance while on therapy and subsequent clinical failure. In the current case, the MRSA strain became resistant to vancomycin, rifampin, and daptomycin during therapy but the patient was successfully treated using salvage combination therapy with high dose daptomycin and TMP/SMX. Development of de novo resistance to vancomycin and daptomycin during therapy of MRSA infections occurs infrequently. The exact mechanisms by which MRSA strains develop resistance to daptomycin during vancomycin therapy are unclear, it has been suggested that reduced susceptibility to daptomycin is associated with transition of vancomycin-susceptible phenotype to a vancomycin-intermediate S. aureus (VISA) phenotype through a vancomycin-resistant S. aureus (hVISA) intermediary. Nevertheless, emergence of daptomycin nonsusceptibility has also been documented in the absence of vancomycin exposure. The mechanism of daptomycin nonsusceptibility remains to be elucidated.

Table 1. Susceptibility testing of MRSA isolates during therapy with various antimicrobial agents.

<table>
<thead>
<tr>
<th>Sample date</th>
<th>Vancomycin, MIC, mg/L</th>
<th>Rifampin</th>
<th>Gentamycin</th>
<th>Linezolid</th>
<th>TMP/SMX</th>
<th>Daptomycin, MIC, mg/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 1</td>
<td>1 (S)e</td>
<td>S</td>
<td>R</td>
<td>0.75 (S)</td>
<td>S</td>
<td>0.75 (S)</td>
</tr>
<tr>
<td>Day 5</td>
<td>1.5 (S)</td>
<td>R</td>
<td>R</td>
<td>0.75 (S)</td>
<td>S</td>
<td>0.75 (S)</td>
</tr>
<tr>
<td>Day 7</td>
<td>1.5 (S)</td>
<td>R</td>
<td>R</td>
<td>0.75 (S)</td>
<td>S</td>
<td>1 (S)</td>
</tr>
<tr>
<td>Day 10</td>
<td>&gt; 2 (R)</td>
<td>R</td>
<td>R</td>
<td>0.75 (S)</td>
<td>S</td>
<td>1.5 (R)</td>
</tr>
</tbody>
</table>

MIC, minimal inhibitory concentration; TMP/SMX, trimethoprim-sulfamethoxazole; S, susceptible; R, resistant.

Table 2. Antimicrobial agents administered during hospital stay along with MRSA bacteremia status.

<table>
<thead>
<tr>
<th>Antimicrobial agents</th>
<th>ICU</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
<th>13</th>
<th>14</th>
<th>15</th>
<th>16</th>
<th>17</th>
<th>18</th>
<th>19</th>
<th>20</th>
<th>21</th>
<th>22</th>
<th>23</th>
<th>24</th>
<th>25</th>
<th>26</th>
<th>27</th>
<th>28</th>
<th>29</th>
<th>30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vancomycin</td>
<td></td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Rifampin</td>
<td></td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Piperacillin-tazobactam</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Daptomycin (dose)</td>
<td></td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Oxacillin</td>
<td></td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>TMP-SMX</td>
<td></td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Amikacin</td>
<td></td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
</tbody>
</table>

MRSA bacteremia status: from Day 1 to Day 24. For daptomycin: ● dose 10 mg/kg, ▲ dose 12 mg/kg.
tibility in *S. aureus* is not completely understood, but has been linked to alterations in cell wall thickening, alterations in surface charge, membrane phospholipid asymmetry, and drug binding.17

There is a growing concern regarding clinical failure of treatment for complicated MRSA infections. Treatment options for persistent MRSA bacteremia or bacteremia due to VISA or vancomycin-resistant *S. aureus* (VRSA), include vancomycin-based therapy with semisynthetic penicillins, cephalosporins,1 beta-lactam-beta-lactamase inhibitor combinations, or carbapenems.18 It has been suggested that synergy results from a reduction in cell wall thickness caused by beta-lactam exposure with a reduction in sequestration of the glycopeptides. Similarly, daptomycin-based therapy was evaluated using combination with beta-lactams, ceftaroline, and TMP/SMX.19,20 To date, several other combinations have been evaluated including ceftaroline-based therapy, linezolid-based therapy, quinupristin/dalfopristin, telavancin, and trimethoprim/sulfamethoxazole-based therapy.19 Current recommendations suggest using combination antibiotic therapy for salvage treatment of MRSA bacteremia.15 Despite the fact that the MRSA strain was persistently susceptible to linezolid we chose not to administer a linezolid-based salvage therapy for two reasons. First, unlike vancomycin and daptomycin, linezolid is bacteriostatic, and second, a previous study showed that in patients with persistent MRSA bacteremia while receiving vancomycin, a switch to linezolid therapy did not lead to better outcomes than those in whom vancomycin was continued.21

**Conclusions**

The case described exemplifies the growing complexity of treating MRSA infections especially when do novo resistance to antimicrobial therapy evolves during therapy. Lastly, the patient succumbed to death few days after clearance of MRSA bacteremia, autopsy was refused by the patient’s family. We hypothesize that his death was caused by dislodgement of the SVC thrombus to the pulmonary trunk causing massive pulmonary embolism. Notwithstanding the tragic outcome and given his hemodynamically stable condition and lack of signs of SVC syndrome, we believe that the decision to treat him only with anticoagulation while maintaining therapeutic anti Xa levels was sensible and in accordance with current guidelines.10

**References**